Doug Hampton
Hyperpigmentation Treatment Market to Reach $10.5 Billion, Globally, by 2032 at 7.5% CAGR: Allied Market Research
Changes in beauty standards globally and surge in geriatric population are expected to drive the growth of the hyperpigmentation treatment market. PORTLAND, Ore., March 11, 2024 /PRNewswire/ — Allied Market Research published a report, titled, “Hyperpigmentation Treatment Market by Treatment Type (Topical Agents, Photo Therapy, and Others), Disorder Type (Age Spot, Melasma, and Others), and End User … Read more
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase … Read more
Assistance on the Way for Low-Income Older Americans
ARLINGTON, Va., March 9, 2024 /PRNewswire/ — The following is a statement from Ramsey Alwin, President and CEO of the National Council on Aging (NCOA), on yesterday’s passage of the federal appropriations package in the Senate: “We applaud Congress for funding critical assistance for low-income older Americans in today’s federal appropriations package. The $62.5 million … Read more
A $4.84 Billion Industry by 2029, Driven by a Large Pool of Target Patient Population, Increasing Elderly Population, and Chronic Disease Prevalence
DUBLIN, March 8, 2024 /PRNewswire/ — The “Global Hospital Beds Market – Focused Insights 2024-2029” report has been added to ResearchAndMarkets.com’s offering. The global hospital beds market was valued at $3.66 billion in 2023 and is expected to reach a value of $4.84 billion by 2029, growing at a CAGR of 4.71% from 2023-2029 The global hospital … Read more
BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order
VANCOUVER, BC, March 8, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company”) today announced that the Ontario Securities Commission (the “OSC“), as the Company’s principal regulator, on February 29, 2024, granted the Company’s previously announced application for the imposition of a management cease trade order under National Policy 12-203 … Read more
ADAMEVE.COM ASKS “ARE AMERICANS’ REPRODUCTIVE RIGHTS BEING TAKEN AWAY?”
HILLSBOROUGH, N.C., March 7, 2024 /PRNewswire/ — Adam & Eve and adameve.com, America’s most trusted source for adult products, are always up for asking the hard questions when it comes to sex in our country. This month, the company surveyed over 1000 people asking if they felt that Americans’ reproductive rights are being taken away. And … Read more
Amerikanische, finnische und kanadische Regierung finanzieren Sauerstoffanlage in der Sonderwirtschaftszone Tatu City, Kenia
Projekt zur Bekämpfung der Kindersterblichkeitsrate und zur Verringerung der fötalen Notlage in Ostafrika TATU CITY, Kenia, 6. März 2024 /PRNewswire/ — Die Regierungen der Vereinigten Staaten, Finnlands und Kanadas finanzieren eine nachhaltige, zugängliche und erschwingliche Anlage zur Herstellung von medizinischem Sauerstoff in der Sonderwirtschaftszone (SEZ) von Tatu City, der 5.000 Hektar großen neuen Stadt vor … Read more
Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma USA – English India – English
The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its open readout at 66 progression events, expected in summer 2024. PALMA DE MALLORCA, Spain, March … Read more
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer USA – English APAC – Traditional Chinese APAC – English
ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, and AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, … Read more